ASSOCIATION FOR MOLECULAR PATHOLOGY v. MYRIAD GENETICS, INC.: PROGRESS BY PRINCIPLES.
- Published in:
- Journal of Health Care Law & Policy, 2015, v. 18, n. 1, p. 141
- By:
- Publication type:
- Article
Works matching DE "ASSOCIATION for Molecular Pathology v. Myriad Genetics Inc."
Results: 52
1
2
ASSOCIATION FOR MOLECULAR PATHOLOGY V. MYRIAD GENETICS: A CRITICAL REASSESSMENT.
- Published in:
- Michigan Technology Law Review, 2020, v. 27, n. 1, p. 1
- By:
- Publication type:
- Article
3
Patent Eligibility Post-Myriad: A Reinvigorated Judicial Wildcard of Uncertain Effect.
- Published in:
- 2014
- By:
- Publication type:
- Essay
4
A MYRIAD OF SOLUTIONS? A GUIDE FOR BIOTECH COMPANIES IN RESPONSE TO THE MYRIAD & MAYO DECISIONS.
- Published in:
- Elon Law Review, 2015, v. 7, n. 1, p. 431
- By:
- Publication type:
- Article
5
PERSONALIZED MEDICINE IN THE INFORMATION AGE: MYRIAD'S DE FACTO MONOPOLY ON BREAST CANCER RESEARCH.
- Published in:
- SMU Law Review, 2015, v. 68, n. 2, p. 537
- By:
- Publication type:
- Article
6
LIFE, LIBERTY, AND THE PURSUIT OF GENETIC INFORMATION.
- Published in:
- Alabama Law Review, 2014, v. 65, n. 3, p. 625
- By:
- Publication type:
- Article
7
PATENTABLE SUBJECT MATTER: A MYRIAD OF PROBLEMS.
- Published in:
- Alabama Law Review, 2014, v. 65, n. 3, p. 815
- By:
- Publication type:
- Article
8
ARIOSA DIAGNOSTICS V. SEQUENOM: METASTASIS OF MAYO AND MYRIAD AND THE EVISCERATION OF PATENT ELIGIBILITY FOR MOLECULAR DIAGNOSTICS.
- Published in:
- Berkeley Technology Law Journal, 2016, v. 31, p. 495, doi. 10.15779/Z38RG35
- By:
- Publication type:
- Article
9
STEMMING THE TIDE: STEM CELL INNOVATION IN THE MYRIAD-MAYO-ROSLIN ERA.
- Published in:
- Berkeley Technology Law Journal, 2015, v. 30, p. 567
- By:
- Publication type:
- Article
10
Applying Doctrine of Equivalents Tests to Products of Nature Decisions.
- Published in:
- Texas Intellectual Property Law Journal, 2016, v. 24, n. 2, p. 245
- By:
- Publication type:
- Article
11
PATENTS AS DATA AGGREGATORS IN PERSONALIZED MEDICINE.
- Published in:
- 2015
- By:
- Publication type:
- Essay
12
ARE ALL GENES EQUAL?
- Published in:
- Journal of Science & Technology Law, 2014, v. 20, n. 1, p. 1
- By:
- Publication type:
- Article
13
A Framework for Understanding Ethical and Efficiency Issues in Pharmaceutical Intellectual Property Litigation.
- Published in:
- Journal of Business Ethics, 2015, v. 132, n. 3, p. 505, doi. 10.1007/s10551-014-2365-7
- By:
- Publication type:
- Article
14
The Supreme Court Renders a Decision on Gene Patents.
- Published in:
- Journal of the Association of Genetic Technologists, 2013, v. 39, n. 3, p. 107
- By:
- Publication type:
- Article
15
US Supreme Court's Decision on the Patent Ineligibility of Human Genes BRCA1/BRCA2 as Products of Nature.
- Published in:
- Journal of Commercial Biotechnology, 2015, v. 21, n. 4, p. 3, doi. 10.5912/jcb721
- By:
- Publication type:
- Article
16
VIROTECH PATENTS, VIROPIRACY, AND VIRAL SOVEREIGNTY.
- Published in:
- Arizona State Law Journal, 2013, v. 45, n. 4, p. 1563
- By:
- Publication type:
- Article
17
THE CURRENT APPLICATION OF THE MYRIAD AND MAYO/ALICE RULINGS ON PATENT ELIGIBILITY: INCONSISTENT RESULTS AND CONTRADISTINGUISHING BIOTECHNOLOGY PRODUCTS.
- Published in:
- Cardozo Arts & Entertainment Law Journal, 2019, v. 38, n. 1, p. 183
- By:
- Publication type:
- Article
18
Morality: An Important Consideration at the Patent Office.
- Published in:
- California Law Review, 2020, v. 108, n. 1, p. 267, doi. 10.15779/Z38222R644
- By:
- Publication type:
- Article
19
US Supreme Court addresses patent eligibility of isolated DNA and cDNA in Myriad V.
- Published in:
- Journal of Intellectual Property Law & Practice, 2013, v. 8, n. 11, p. 811, doi. 10.1093/jiplp/jpt156
- By:
- Publication type:
- Article
20
Myriad effects.
- Published in:
- 2013
- By:
- Publication type:
- Opinion
21
A QUANTITATIVE APPROACH TO DETERMINING PATENTABLE SUBJECT MATTER.
- Published in:
- Harvard Journal of Law & Technology, 2017, v. 30, n. 2, p. 629
- By:
- Publication type:
- Article
22
PATENTING NATURAL PRODUCTS AFTER MYRIAD.
- Published in:
- Harvard Journal of Law & Technology, 2017, v. 30, n. 2, p. 569
- By:
- Publication type:
- Article
23
THE MYRIAD REASONS TO HIT "RESET" ON PATENT-ELIGIBILITY JURISPRUDENCE.
- Published in:
- Loyola of Los Angeles Law Review, 2013, v. 47, n. 1, p. 117
- By:
- Publication type:
- Article
24
AFTER PROMETHEUS, ARE HUMAN GENES PATENTABLE SUBJECT MATTER?
- Published in:
- Duke Law & Technology Review, 2013, v. 11, n. 2, p. 434
- By:
- Publication type:
- Article
25
ASSOCIATION FOR MOLECULAR PATHOLOGY V. MYRIAD GENETICS, INC: WHAT ARE THE EFFECTS ON CLONING EXTINCT ANIMALS AND AGRICULTURE NOW THAT CDNA IS PATENTABLE?
- Published in:
- Drake Journal of Agricultural Law, 2014, v. 19, n. 3, p. 347
- By:
- Publication type:
- Article
26
WHO DEFINES "HEALTHY"? ETHICAL DILEMMAS ACROSS COMPETING INTEREST GROUPS ON GENETIC MANIPULATION AND GENE PATENTS.
- Published in:
- DePaul Journal of Health Care Law, 2015, v. 17, n. 1, p. 47
- By:
- Publication type:
- Article
27
AFTER MYRIAD: RECONSIDERING THE INCENTIVES FOR INNOVATION IN THE BIOTECH INDUSTRY.
- Published in:
- Michigan Telecommunications & Technology Law Review, 2014, v. 21, n. 1, p. 141
- By:
- Publication type:
- Article
28
Recent Pharmaceutical Patent Decisions in the United States.
- Published in:
- Journal of Intellectual Property Rights, 2014, v. 19, n. 1, p. 18
- By:
- Publication type:
- Article
29
INCENTIVE FOR INNOVATION OR INVITATION TO INHUMANITY?: A HUMAN RIGHTS ANALYSIS OF GENE PATENTING AND THE CASE OF MYRIAD GENETICS.
- Published in:
- Utah Law Review, 2012, v. 2012, n. 1, p. 497
- By:
- Publication type:
- Article
30
Genes, Patents, and the Supreme Court.
- Published in:
- Research Technology Management, 2013, v. 56, n. 6, p. 4
- By:
- Publication type:
- Article
31
METAPHOR AFTER MYRIAD: THE EFFECT OF LEGAL RHETORIC ON INTELLECTUAL PROPERTY PROTECTION FOR BIOLOGICAL SEQUENCES.
- Published in:
- IDEA: The Intellectual Property Law Review, 2017, v. 57, n. 3, p. 519
- By:
- Publication type:
- Article
32
Patenting nature—a comparative perspective.
- Published in:
- Journal of Law & the Biosciences, 2018, v. 5, n. 3, p. 550, doi. 10.1093/jlb/lsy021
- By:
- Publication type:
- Article
33
Ruling to Overturn Human Gene Patents Is a Huge Win for Women's Health.
- Published in:
- GeneWatch, 2013, v. 26, n. 2/3, p. 7
- By:
- Publication type:
- Article
34
AMP v. Myriad: Preliminary Reflections.
- Published in:
- GeneWatch, 2013, v. 26, n. 2/3, p. 5
- By:
- Publication type:
- Article
35
Patent Protection for Genetic Innovation: Monsanto and Myriad.
- Published in:
- Cato Supreme Court Review, 2012, p. 283
- By:
- Publication type:
- Article
36
Patents at the Supreme Court: It Could've Been Worse.
- Published in:
- Cato Supreme Court Review, 2012, p. 267
- By:
- Publication type:
- Article
37
Orphan Black, biocapital and venture science.
- Published in:
- Science Fiction Film & Television, 2018, v. 11, n. 3, p. 372, doi. 10.3828/sfftv.2018.24
- By:
- Publication type:
- Article
38
THE SHAPE OF THINGS TO COME: A COHESIVE APPROACH TO PATENT-ELIGIBLE SUBJECT MATTER AND BIOTECHNOLOGY.
- Published in:
- Wake Forest Law Review, 2014, v. 49, n. 5, p. 1519
- By:
- Publication type:
- Article
39
ROLLING WITH THE PUNCHES SINCE 1793: THE PATENT SYSTEM BEFORE AND AFTER ASSOCIATION FOR MOLECULAR PATHOLOGY V. MYRIAD GENETICS, INC., 133 S. CT. 2107 (2013).
- Published in:
- Southern Illinois University Law Journal, 2017, v. 41, n. 2, p. 305
- By:
- Publication type:
- Article
40
A LESSON LEARNED FROM MYRIAD: THE AFFORDABLE CARE ACT AS BOTH AN INCENTIVE AND AN ALTERNATIVE FOR INVALIDATING STEM CELL PATENTS.
- Published in:
- Indiana Law Review, 2015, v. 48, n. 2, p. 723, doi. 10.18060/4806.0010
- By:
- Publication type:
- Article
41
I'll Have Mayo With My Myriad: The Effect of Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Association for Molecular Pathology v. U.S. Patent and Trademark Office on Patent Licensees and Licensors.
- Published in:
- Journal of Corporation Law, 2014, v. 39, n. 3, p. 639
- By:
- Publication type:
- Article
42
Federal Circuit Holds Isolated DNA Is Patent-Eligible - Association for Molecular Pathology v. United States Patent and Trademark Office (Myriad III).
- Published in:
- American Journal of Law & Medicine, 2012, v. 38, n. 4, p. 755, doi. 10.1017/s0098858800001027
- By:
- Publication type:
- Article
43
Patenting Biologicals.
- Published in:
- Bench & Bar of Minnesota, 2013, v. 70, n. 8, p. 22
- By:
- Publication type:
- Article
44
INTELLECTUAL PROPERTY.
- Published in:
- Bench & Bar of Minnesota, 2013, v. 70, n. 7, p. 39
- By:
- Publication type:
- Article
45
Mayo, Myriad, and a Muddled Analysis: Do Recent Changes to the Patentable Subject Matter Doctrine Threaten Patent Protections for Epigenetics-Based Inventions?
- Published in:
- Minnesota Law Review, 2018, v. 102, n. 5, p. 2229
- By:
- Publication type:
- Article
46
Gene patents in the dock.
- Published in:
- Nature, 2013, v. 496, n. 7444, p. 150, doi. 10.1038/496150a
- By:
- Publication type:
- Article
47
The Product of Nature Doctrine in the Myriad Saga II.
- Published in:
- European Journal of Risk Regulation, 2013, v. 4, n. 3, p. 409, doi. 10.1017/S1867299X00002725
- By:
- Publication type:
- Article
48
Intellectual Property.
- Published in:
- Mercer Law Review, 2014, v. 65, n. 4, p. 1049
- By:
- Publication type:
- Article
49
PATENTS WITHOUT TEETH: WHOLE GENOME SEQUENCING AND GENE PATENT INFRINGEMENT AFTER AMP v. MYRIAD.
- Published in:
- Jurimetrics: The Journal of Law, Science & Technology, 2013, v. 54, n. 1, p. 65
- By:
- Publication type:
- Article
50
Are the gene-patent storm clouds dissipating? A global snapshot.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 4, p. 347, doi. 10.1038/nbt.3182
- By:
- Publication type:
- Article